Download PDF
Thromb Haemost 1998; 80(01): 186-191
DOI: 10.1055/s-0037-1615161
Rapid Communication
Schattauer GmbH

Effective Use of BCH-2763, a New Potent Injectable Direct Thrombin Inhibitor, in Combination with Tissue Plasminogen Activator (tPA) in a Rat Arterial Thrombolysis Model

Isabelle Deschênes
From BioChem Therapeutic Inc., Laval, Quebec, Canada
,
Carolyn D. Finkle
From BioChem Therapeutic Inc., Laval, Quebec, Canada
,
Peter D. Winocour
From BioChem Therapeutic Inc., Laval, Quebec, Canada
› Author Affiliations
Further Information

Publication History

Received 19 November 1997

Accepted after revision 11 March 1998

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

Summary

Current therapeutic use of heparin as an adjunct to thrombolytic therapy for myocardial infarction is suboptimal with respect to efficacy and bleeding risk. In a rat carotid arterial thrombolysis model (FeCl3-induced injury) we evaluated the combined effect of tPA (2.0 mg/kg/ 30 min) with our potent injectable direct thrombin inhibitor, BCH-2763 (Ki 0.11 nM; MW 1.5 kDa), which, unlike heparin, inhibits bound and free thrombin; comparisons were with standard heparin (SH), other direct thrombin inhibitors, r-hirudin (MW 6.5 kDa) and hirulog (MW 2.3 kDa), or tPA alone. Time to lysis (TL), patency time (PT), aPTT (fold increase) and bleeding time (BT) were determined. ED100 (100% of rats reperfused) for BCH-2763, hirulog or r-hirudin was 1, 3 or 2 mg/kg/60 min, respectively; 67% of rats reperfused with SH at the highest dose tested (220 U/kg/60 min) and 43% with tPA alone. At these doses, TL (min) was shorter (p <0.01) with BCH-2763 (0.5 ± 0.1), hirulog (3.3 ± 2.3) or r-hirudin (2.3 ± 1.0) than SH (66.3 ± 30.8) or tPA alone (93.4 ± 21.4). The aPTT fold increase after 15 min infusion was markedly greater (p <0.001) for SH (32.0 ± 0.8) than BCH-2763 (3.7 ± 0.5), hirulog (5.2 ± 0.3) or r-hirudin (4.5 ± 0.8) in combination with tPA or tPA alone (1.1 ± 0.1). In addition, the BT (min) for BCH-2763 (3.0 ± 0.4) was similar to tPA alone (1.6 ± 0.3), but prolonged (p <0.05) for hirulog (7.5 ± 2.7), r-hirudin (6.6 ± 0.8) or SH (7.3 ± 1.8). Comparisons at same aPTT fold increase revealed that in combination with tPA, BCH-2763 required a lower anticoagulant level to shorten the TL and prolong the PT than hirulog, r-hirudin or SH. Thus, in this rat arterial thrombolysis model direct thrombin inhibitors are more effective than SH as antithrombotic adjuncts to tPA. BCH-2763 is effective at a lower gravimetric dose and more modest aPTT fold increase than hirulog or r-hirudin with less alteration in haemostasis, which may confer an improved safety index.

 

  • References

  • 1 Becker RC. Seminars in thrombosis, thrombolysis and vascular biology (4. fibrinolysis). Cardiology 1991; 79: 188-210.
    CrossrefPubMedGoogle Scholar
  • 2 Collen D, Lijnen HR, Todd PA, Goa KL. Tissue-type plasminogen activator a review of its pharmacology and therapeutic use as a thrombolytic agent. Drugs 1989; 38: 346-88.
    CrossrefPubMedGoogle Scholar
  • 3 Sobel BE. Thrombolysis in the Treatment of Acute Myocardial Infarction. In: Thrombosis in Cardiovascular Disorders. Fuster V, Verstraete M. eds. Saunders; Philadelphia, PA: 1992. pp. 289-326.
    Google Scholar
  • 4 Kleiman NS. Clinical trials of conjunctive anticoagulant strategies in thrombolysis. Coronary Artery Disease 1996; 7: 508-15.
    CrossrefPubMedGoogle Scholar
  • 5 Weitz JI, Hirsh J. Antithrombins: their potential as antithrombotic agents. Annu Rev Med 1992; 43: 9-16.
    CrossrefPubMedGoogle Scholar
  • 6 Weitz JI. New anticoagulant strategies current status and future potential. Drugs 1994; 48: 485-97.
    CrossrefPubMedGoogle Scholar
  • 7 Weitz JI, Clikk RM, Ginsberg JS, Hirsh J, Théroux P. New antithrombotics. Chest 1995; 108: 471S-85S.
    CrossrefPubMedGoogle Scholar
  • 8 Kéréveur A, Samama MM. New antithrombotic agents. La Presse Médicale 1995; 24: 1777-87.
    PubMedGoogle Scholar
  • 9 Freek WA, Verheugt AM, Lagrand VK, van Eenige MJ. Reocclusion: the flip side of coronary thrombolysis. J Am Coll Cardiol 1996; 27: 766-73.
    CrossrefPubMedGoogle Scholar
  • 10 Chesebro JH, Knatterud G, Robert R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hills D Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142-54.
    CrossrefPubMedGoogle Scholar
  • 11 TIMI Study Group.. The thrombolysis in myocardial infarction trial: phase I findings. N Engl J Med 1985; 312: 932-6.
    PubMedGoogle Scholar
  • 12 Meijer A, Verheugt FW, Werter CJPJ, Lie KI, Van Der Pol JM, Van Eenige MJ. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT study. Circulation 1993; 87: 1524-30.
    CrossrefPubMedGoogle Scholar
  • 13 Sobel BE. Coronary thrombolysis and the new biology. J Am Coll Cardiol 1989; 14: 850-60.
    CrossrefPubMedGoogle Scholar
  • 14 Collen D, Topol EJ, Tiefenbrunn AJ. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation 1984; 70: 1012-17.
    CrossrefPubMedGoogle Scholar
  • 15 Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90: 1522-36.
    CrossrefPubMedGoogle Scholar
  • 16 Fenton JW, Ni F, Witting JI, Brezniak DV, Anderson TT, Malik AB. The Rational Design of Thrombin-Directed Antithrombotics. In: The Design of Synthetic Inhibitors of Thrombin. Claeson G. et al. eds. Plenum Press; New York, NY: 1993. pp. 1-13.
    Google Scholar
  • 17 Catella-Lawson F. Direct thrombin inhibitors in cardiovascular disease. Coronary Artery Disease 1997; 8: 105-11.
    CrossrefPubMedGoogle Scholar
  • 18 Chesebro JH. Direct thrombin inhibition superior to heparin during and after thrombolysis. Circulation 1997; 96: 2118-20.
    CrossrefPubMedGoogle Scholar
  • 19 Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991; 83: 1048-56.
    CrossrefPubMedGoogle Scholar
  • 20 Martin U, Dörge L, Fisher S. Comparison of desulfatohirudin (REVASC) and heparin as adjunct to thrombolytic therapy with reteplase in a canine model of coronary thrombosis. Br J Pharmacol 1996; 118: 271-6.
    CrossrefPubMedGoogle Scholar
  • 21 Rübsamen K, Hornberger W. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin. Thromb Haemost 1996; 76: 105-10.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Rigel DF, Olson RW, Lappe RW. Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis. Circulation Research 1993; 72: 1091-102.
    CrossrefPubMedGoogle Scholar
  • 23 Maraganore JM. Hirudin and hirulog: advances in antithrombotic therapy. Perspectives in drug discovery and design 1993; 1: 461-78.
    PubMedGoogle Scholar
  • 24 Mattsson C, Björkman JA, Ulvinge JC. Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis. Fibrinolysis & Proteolysis 1997; 11: 121-8.
    CrossrefPubMedGoogle Scholar
  • 25 Rübsamen K, Eschenfelder V. Effect of recombinant hirudin (LU52369) on reocclusion rates after thrombolysis in rabbits. Haemostasis 1991; 21 (Suppl. 01) 93-8.
    PubMedGoogle Scholar
  • 26 Kaiser B, Simon A, Markwardt F. Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis. Thromb Haemost 1990; 63: 44-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Agnelli G, Pascucci C, Cosmi B, Nenci G. Effects of hirudin and heparin on the binding of new fibrin to the thrombus in t-PA treated rabbits. Thromb Haemost 1991; 66: 592-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Agnelli G, Pascucci C, Cosmi B, Nenci G. Effects of therapeutic doses of heparin on thrombolysis with tissue-type plasminogen activator in rabbits. Blood 1990; 76: 2030-6.
    PubMedGoogle Scholar
  • 29 Lenfors S, Marberg L, Wikström S, Jonsson U, Eriksson AW, Gustafsson D. A new rat model of arterial thrombosis with a platelet-rich head and an erythrocyte-rich tail: thrombolysis experiments with specific thrombin inhibition. Blood Coagulation and Fibrinolysis 1993; 4: 263-71.
    CrossrefPubMedGoogle Scholar
  • 30 Klement P, Borm A, Hirsh J, Maraganore J, Wilson G, Weitz J. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model. Thromb Haemost 1992; 68: 64-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Mruk JS, Zoldhelyi P, Webster MWI, Heras M, Grill DE, Holmes DR, Fuster V, Chesebro JH. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effect of recombinant hirudin, heparin, or aspirin. Circulation 1999; 03: 792-9.
    PubMedGoogle Scholar
  • 32 Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74: 1-23.
    CrossrefPubMedGoogle Scholar
  • 33 Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochem 1990; 29: 7095-107.
    CrossrefPubMedGoogle Scholar
  • 34 Cannon CP, McCabe CH, Henry TD. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994; 23: 993-1003.
    CrossrefPubMedGoogle Scholar
  • 35 Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico.. GISSI-2: a factorial randomised trial of alteplase vs streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71.
    PubMedGoogle Scholar
  • 36 ISIS-3.. A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-70.
    CrossrefPubMedGoogle Scholar
  • 37 Théroux P, Perez-Villa F, Waters D, Lespérance J, Shabani F, Bonan R. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995; 91: 2132-8.
    CrossrefPubMedGoogle Scholar
  • 38 White HD, Aylward PE, Frey MJ, Adgey AAJ, Nair R, Hillis WS, Shalev Y, Brown MA, French JK, Collins R, Maraganore J, Adelman B. on behalf of the Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997; 96: 2155-61.
    CrossrefPubMedGoogle Scholar
  • 39 Antmann EM. for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-30.
    CrossrefPubMedGoogle Scholar
  • 40 Global Use of Strategies to Open Coronary Arteries (GUSTO) IIa Investigators.. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-7.
    CrossrefPubMedGoogle Scholar
  • 41 Neuhaus KL, con Essen R, Tebbe U. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft leitender kardiologischer Krankenhausartze (ALKK). Circulation 1994; 90: 1638-42.
    CrossrefPubMedGoogle Scholar
  • 42 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators.. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. New Engl J Med 1996; 335: 775-81.
    CrossrefPubMedGoogle Scholar
  • 43 Antmann EM. for the TIMI 9B Investigators. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 1996; 94 (05) 911-21.
    CrossrefPubMedGoogle Scholar
  • 44 Fitzgerald GA. The human pharmacology of thrombin inhibition. Coronary Artery Disease 1996; 7: 911-8.
    CrossrefPubMedGoogle Scholar
  • 45 Finkle CD, St Pierre A, Leblond L, Deschênes I, DiMaio J, Winocour PD. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis; comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb Haemost 1998; 79: 431-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 DiMaio J, Ni F, Gibbs B, Konishi Y. A new class of potent thrombin inhibitors that incorporates a scissile pseudopeptide bound. FEBS 1991; 282: 47-52.
    CrossrefPubMedGoogle Scholar
  • 47 Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res11 1990; 60: 269-80.
    PubMedGoogle Scholar
  • 48 Berry CN, Girard D, Lochot S, Lecoffre C. Antithrombotic actions of argatroban in rat models of venous ‘mixed’ and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol 1994; 113: 1209-14.
    CrossrefPubMedGoogle Scholar
  • 49 Jang I-K, Gold HK, Kiskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. Circulation 1989; 79: 920-8.
    CrossrefPubMedGoogle Scholar
  • 50 Yao S-K, McNatt J, Anderson HV, Eidt J, Cui K, Golino P, Glas-Green-waltz P, Maraganore J, Buja LM, Willerson JT. Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion. Am Physiological Society 1992; H374-9.
    PubMedGoogle Scholar
  • 51 Voytik S, Badylak F, Burke S, Klabunde RE, Henkin J. The protective effect of heparin in a dog model of rethrombosis following pharmacologic thrombolysis. Thromb Haemost 1990; 64: 438-44.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Weitz JI, Hudoba M, Massel D, Maraganore JM, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
    CrossrefPubMedGoogle Scholar